Nivalis Therapeutics Reports Second Quarter 2016 Financial Results
August 01, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
Cavosonstat achieves significant phase 2 enrollment milestones during quarter BOULDER, Colo., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage...
Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
July 07, 2016 07:00 ET
|
Nivalis Therapeutics, Inc.
- Study is Evaluating N91115 in Patients Homozygous for the F508del-CFTR Mutation and Being Treated with Orkambi™ - “Cavosonstat” Approved as the Unique Non-proprietary or Generic Name for N91115 -...
Nivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
July 06, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., July 06, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference
June 15, 2016 07:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., June 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference
June 01, 2016 07:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., June 01, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
May 16, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
- Study to Evaluate N91115 in Patients Heterozygous for F508del-CFTR and a Gating Mutation - Data Expected in the First Half of 2017 BOULDER, Colo., May 16, 2016 (GLOBE NEWSWIRE) -- Nivalis...
Nivalis Therapeutics Reports First Quarter 2016 Financial Results
May 02, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
- Two Phase 2 Studies in Cystic Fibrosis Now EnrollingBOULDER, Colo., May 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage pharmaceutical company focused...
Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 22, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., April 22, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery
April 18, 2016 07:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., April 18, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis
April 05, 2016 08:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., April 05, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...